Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Appili Therapeutics Inc.
No Price
Closing Price XTSE 01.05.2026:
0,02 CAD
01.05.2026 19:59
Current Prices from Appili Therapeutics Inc.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
TSX
APLI.TO
CAD
01.05.2026 19:59
0,02 CAD
0,005 CAD
+33,33 %
UTC
APLIF
USD
01.05.2026 19:09
0,01 USD
-0,0005 USD
-3,33 %
Share Float & Liquidity
Free Float88,76 %
Shares Float113,93 M
Shares Outstanding128,37 M
Company Profile for Appili Therapeutics Inc. Share
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
